These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12422001)

  • 1. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
    Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Mezières M; Alexandre C; Dougados M
    Rheumatology (Oxford); 2002 Nov; 41(11):1280-5. PubMed ID: 12422001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A short-term efficacy and safety study of infliximab in active ankylosing spondylitis].
    Huang F; Zhang LY; Zhang JL; Zhang FC; Liang DF; Deng XH; Guo JH; Zhu J; Zhao W; Li XF; Hou Y
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):122-6. PubMed ID: 16624120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
    Van den Bosch F; Kruithof E; Baeten D; De Keyser F; Mielants H; Veys EM
    Ann Rheum Dis; 2000 Jun; 59(6):428-33. PubMed ID: 10834859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study.
    Temekonidis TI; Alamanos Y; Nikas SN; Bougias DV; Georgiadis AN; Voulgari PV; Drosos AA
    Ann Rheum Dis; 2003 Dec; 62(12):1218-20. PubMed ID: 14644863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
    Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
    Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
    Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
    Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice.
    Haibel H; Song IH; Rudwaleit M; Listing J; Hildemann S; Sieper J
    Clin Exp Rheumatol; 2008; 26(2):247-52. PubMed ID: 18565245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
    Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
    Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis.
    Venetsanopoulou AI; Voulgari PV; Alamanos Y; Papadopoulos CG; Markatseli TE; Drosos AA
    Rheumatol Int; 2007 Aug; 27(10):935-9. PubMed ID: 17357804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Alten R; Burmester G; Gromnica-Ihle E; Haibel H; Schewe S; Schneider M; Sörensen H; Zeidler H; Visvanathan S; Sieper J; Braun J
    J Rheumatol; 2007 Mar; 34(3):510-5. PubMed ID: 17299842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study.
    Moreno M; Gratacós J; Torrente-Segarra V; Sanmarti R; Morlà R; Pontes C; Llop M; Juanola X;
    Arthritis Res Ther; 2019 Apr; 21(1):88. PubMed ID: 30953541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.